Published in final edited form as:

Cancer Metastasis Rev. 2017 June ; 36(2): 199–213. doi:10.1007/s10555-017-9682-0.

Platelet “First Responders” in Wound Response, Cancer, and Metastasis

David G. Menter^{1,*}, Scott Kopetz¹, Ernest Hawk², Anil K. Sood^{3,4,5}, Jonathan M Loree¹, Paolo Gresele⁶, and Kenneth V. Honn^{7,8,9,10}

¹Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA

²Office of the Vice President Cancer Prevention & Population Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA

³Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA

⁴Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA

⁵Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA

⁶Professor of Internal Medicine, Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Via E. Dal Pozzo 06126 Perugia Italy

⁷Bioactive Lipids Research Program, Department of Pathology, Wayne State University, 5101 Cass Ave. 430 Chemistry, Detroit, MI 48202

⁸Distinguished Professor, Department of Pathology, Wayne State University School of Medicine, 431 Chemistry Bldg., Detroit, MI 48202

⁹Professor, Department of Pathology, Wayne State University School of Medicine, 431 Chemistry Bldg., Detroit, MI 48202

¹⁰Cancer Biology Division, Wayne State University School of Medicine, 431 Chemistry Bldg., Detroit, MI 48202

Abstract

Platelets serve as “First Responders” during normal wounding and homeostasis. Arising from bone marrow stem cell lineage megakaryocytes, anucleate platelets can influence inflammation and immune regulation. Biophysically, platelets are optimized due to size and discoid morphology to distribute near vessel walls, monitor vascular integrity and initiate quick responses to vascular lesions. Adhesion receptors linked to a highly reactive filopodia-generating cytoskeleton maximizes their vascular surface contact allowing rapid response capabilities. Functionally,

*Corresponding author: David G. Menter, Ph.D., Assistant Professor, Department of Gastrointestinal Medical Oncology, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard--Unit 0426, Houston, TX 77030, Office: (713) 792-0626, FAX: (713) 792-6375, dmenter@mdanderson.org, Room#: FC10.3004.

There are no conflicts of interest associated with this manuscript.

platelets normally initiate rapid clotting, vasoconstriction, inflammation and wound biology that leads to sterilization, tissue repair and resolution. Platelets also are among the first to sense, phagocytize, decorate, or react to pathogens in the circulation. These platelet first responder properties are commandeered during chronic inflammation, cancer progression and metastasis. Leaky or inflammatory reaction blood vessel genesis during carcinogenesis provides opportunities for platelet invasion into tumors. Cancer is thought of as a non-healing or chronic wound that can be actively aided by platelet mitogenic properties to stimulate tumor growth. This growth ultimately outstrips circulatory support leads to angiogenesis and intravasation of tumor cells into the blood stream. Circulating tumor cells reengage additional platelets, which facilitates tumor cell adhesion, arrest and extravasation and metastasis. This process, along with the hypercoagulable states associated with malignancy is amplified by IL6 production in tumors that stimulate liver thrombopoietin production and elevates circulating platelet numbers by thrombopoiesis in the bone marrow. These complex interactions and the “First Responder” role of platelets during diverse physiologic stresses provides a useful therapeutic target that deserves further exploration.

Keywords

platelet; TCIPA; metastasis; thrombosis; extravasation; CTC

Platelet “First Responder” Properties

“First Responders” describes platelets as active participants in the hemostasis, wounding, immune, and metastatic processes [1,2]. Platelets often remain unheeded during *in vivo* experimental studies or pathologic observations. The primary reason is due to small size/volume (mean platelet volumes range is 9.7–12.8 femtoliter or spheres 2 to 3 μm in diameter) and the lack of a nucleus makes identification more difficult compared to the typical nucleated cell. Although platelets are visible by high magnification light microscopy, ultrastructural analysis is typically done to effectively observe subcellular morphologic or activational structural changes and newer methods may prove even more observationally effective [3–6]. Individual and aggregates of activated platelets can be detected by immunohistochemistry at the microscopic level but this is not a routine approach for pathologists.

Biophysically, resting platelets exhibit a plate-like discoid shape that maximizes planar surface interactions [7–9]. These physical characteristics facilitate their segregation toward the outer fluid shear fields of flowing blood [10–17]. Normal human platelets range between 150,000 – 400,000 per microliter (μl) in numbers with those that concentrate near vessel walls being 2–3 times greater than at the central fluid stream. Platelet flow patterns, near wall excess, and proximity enhance encounters and recognition of any vascular wall lesions or wounds. These platelet recognition properties include the exposure of the subendothelial basement membrane or underlying matrix induced by wounding or endothelial retraction [18–23]. The rapid formation of filopodia facilitated by a variety of adhesion receptors linked to a highly reactive cytoskeleton helps maximize dynamic surface contacts and the rapid response rate of platelets [24–31].

Platelet “First Response” Facilitated Clot/Wound Biology

Normally platelets serve as “First Responders” during the wounding process and hemostasis. A lacerated blood vessel exposes platelets to subendothelial elements that initiate their first response through receptor-based recognition of extracellular matrix. This recognition triggers platelet activation and aggregation. Once activated, within a matter of seconds platelets begin to change shape, degranulate and release proteins, growth factors, bioactive lipids and other factors that recruit additional platelets and immune cells along with initiating thrombogenesis and clotting to fill any exposed gaps.

This process occurs in response to an injury that exposes collagen and extracellular matrix proteins that result in interactions with the exposed endothelium. These first responder interactions are driven by a variety of platelet glycoprotein receptors that can fail in many congenital platelet disorders [32,2]. These receptors can bind extracellular matrix factors that include proteoglycans, laminin, fibronectin, and vitronectin along with various isoforms of collagen. von Willebrand’s Factor (VWF) binds to exposed collagen I, III, and VI fibers. VWF is also recruited into matrix networks by forming tethering fiber strands [33–37].

Platelet surface GPIb forms multimeric complexes that initiate catch bond interactions with exposed tethering fiber strands [33–37]. Catch-slip-tethering bonds cause platelets to begin rolling within blood fluid shear stress fields [33–37]. Four transmembrane proteins contribute to functional GPIb complexes including two 20-kDa GPIX subunits, two 26-kDa GPIb β subunits, two 135-kDa GPIb α subunits, and one central 82-kDa GPV subunit [38,39]. GPIb receptors belong to the LRR receptor family of proteins that are uniquely expressed by platelets [38,39]. Genetic loss of GPIb expression leads to Bernard-Soulier syndrome bleeding disorders [40]. GPIb-IX-V glycosphingolipid domain multimeric complexes interact with VWF multimers [41]. Tethering can also occur with UltraLarge von Willebrand factor (ULVWF) and endothelial cells to attract platelets to these protein strands along with other cells such as leukocytes and potentially tumor cells [42–44]

Platelets contextually encounter numerous circulating ligands, cells, pathogens and extracellular matrix ligands in the bloodstream. Immediate responses are mediated by a variety of integrin receptors through transmembrane glycoprotein α and β heterodimers once ligands are engaged. Resting platelets express low affinity conformation integrins that are bent over protecting binding sites. Once activated, α and β subunits protrude forming high affinity or open binding state that efficiently interact with ligands. Rolling platelet behavior is initiated by multimeric GPIb-complex interactions with VWF activates a key stabilization integrin $\alpha_{IIb}\beta_3$ [45–48] shifting them from a closed to an open state. In the open state, transmembrane $\alpha_{IIb}\beta_3$ heterodimers that are very promiscuous and bind multiple RGD-containing ligands [45–48] that includes: fibrin, fibrinogen, fibronectin, vitronectin, thrombospondin or VWF complexes. Abnormal $\alpha_{IIb}\beta_3$ integrin receptor expression is involved in Glanzmann’s thrombasthenia [49–51].

More selective ligand binding integrins also stabilize interactions with the vascular microenvironment. For example, the collagen receptor $\alpha_2\beta_1$ is a key matrix-stabilizing integrin [52,53]. Once activated, $\alpha_2\beta_1$ stabilizes adhesive contacts and initiates lamellipodia

formation and platelet spreading. In contrast, circulating or extracellular matrix fibronectin is engaged by platelet $\alpha_5\beta_1$ integrin heterodimers [54]. The $\alpha_5\beta_1$ integrin binding is activation state dependent, binding more selectively to fibronectin RGD peptide sites under static conditions. Tyrosine phosphorylation and changes in calcium levels can also facilitate filopodia formation [55]. Platelets also express $\alpha_6\beta_1$ integrin receptors that selectively bind to laminin in the basement membrane and induce filopodia formation [56,57]. The activation of $\alpha_6\beta_1$ integrin receptors typically involves crosstalk with platelet collagen receptor glycoprotein VI (GPVI) to achieve stable adhesion.

Additional receptors are involved in biologic responses of platelets such as GPVI, which belongs to the Ig receptor superfamily and is found exclusively in platelets [58,59]. GPVI is a major collagen receptor that recognizes the quaternary structure of collagen, and activates platelets [60,61]. Platelet GPVI monomers shift from low affinity and signal transduction potential to multimers that gain high affinity collagen periodic structure [41,62–65].

Platelet C-type LECTin-like receptor (CLEC-2/Aggrus) is another platelet receptor that initiates platelet activation through molecular multimerization [66,41,62,67,68]. CLEC-2 binds to mucin glycoprotein podoplanin [69–71]. Podoplanin is expressed on cells of the lymphatic endothelia, type I lung epithelia, choroid plexus epithelia, kidney podocytes, lymph node stroma along with cancer cells and potentiates migration and invasion [69,72,70,71]. Podoplanin is a transmembrane sialomucin glycoprotein [69,41,73,74], which interacts with platelet CLEC-2 receptors triggering signal transduction [41,75,67,68].

Platelet P-selectin is also known as membrane glycoprotein GMP-140 [76,77]. P-selectin binds to P-Selectin Glycoprotein Ligand (PSGL)-1 [78], neutrophil Leukocyte-Endothelial Cell Adhesion Molecule 1 (LECAM-1) [79], Endothelial cell-Leukocyte Adhesion Molecule 1 (ELAM-1) [80], and sialyl Lewis(x) oligosaccharide [81]. P-selectin interaction with a variety of immune cells and endothelial cells is important in mediating inflammation, autoimmunity, and wound healing [82–84]. P-selectins along with L- and E-selectins help tethering and rolling of cells flowing past the vascular luminal surfaces during the initial phases of intravascular adhesive interactions that are stabilized by other receptors [85–91].

Thrombus formation relies on platelet “first responder” mediated rolling, adherence, spreading, migration, aggregation, and stabilization. Nitric oxide, Prostacyclin (PGI_2) and CD39-mediated reduction of local purine nucleotides help maintain the resting state of circulating platelets [92–96]. Injury-induced exposure of subendothelial matrix occurs transient tethering bonds are made between matrix-bound VWF and platelet GPIb-IX-V receptor complexes [33–36,39,37]. Transient tethers support rolling and slow platelet movement. Slower movement permits more intimate interactions between collagen fibers and platelet GPVI surface receptors shift integrins from a closed to an open state [58,59]. Activated $\alpha_2\beta_1$ binding with collagen and $\alpha_{\text{IIb}}\beta_3$ binding to fibrinogen stimulate platelet shape change and degranulation [45–48]. Release of α -granules and dense granules amplifies secondary platelet responses and initiates tissue repair. Activation forms platelets prothrombotic nucleation centers for tissue factor initiated coagulation [97]. Platelets interact with nearby platelets through $\alpha_{\text{IIb}}\beta_3$ receptors and bind fibrinogen and fibrin fibers [45–48]. Progressive cycles of platelet activation, adherence, spreading, migration,

aggregation, and stabilization form a thrombus that builds a fibrin network and entraps other blood cells. Thrombotic plug formation is stabilized and counterbalanced by the disaggregation of platelets and fibrinolysis. Platelets migrate and initiate tissue repair [98–102].

First responder reactions are rapidly enhanced by activating molecules such as thrombin or ADP that are triggered at the cell surface or as a result of the release reaction. Activation results in release of granular contents or molecular export, which include proteins and molecules such as thromboxane A₂ (TXA₂) that amplify the local platelet response to recruit additional platelets to the forming clot and accelerate the thrombogenesis/clotting process [103,104]. The production of TXA₂ along with other lipids initiates vasoconstriction [105,106]. As a primary stimulant of platelet recruitment and aggregation, TXA₂ is among the shorter-lived prostaglandins due to molecular epoxide bond strain in the active part of the molecule that is prone to hydrolysis in <30 seconds [107,108]. These rapid changes accelerate over a matter of minutes and generate a fibrin network that traps and activates more platelets within the forming clot in a cyclic fashion and limits blood loss. This first responder amplification process occurs over approximately a twenty-minute time frame or less and clot maturation and solidification continues for an hour or so and initiates immune cell recruitment and inflammation over the next few days to weeks. Recruitment of fibroblasts and immune cells through platelet-initiated angiogenic repair mechanisms stimulates wound healing and resolution [99]. Proliferation, tissue remodeling and wound repair that resolves normally over a month to a years time-line.

The release of platelet dense granule components influences the vascular microenvironment. The release of calcium and magnesium ions promotes platelet activation and aggregation. The release of nucleotides such as ADP activates platelets through P2Y₁ and P2Y₁₂ receptors [109,110] and stimulates vasoconstriction [111]. The dense granule release or engagement of membrane tetraspanins, CD9, CD63, CD151, Tspan9 and Tspan32, regulates cell surface interactions [112,113]. CD9 is the most abundant platelet tetraspanin and engages Fcγ RIIA, a low-affinity receptor for IgG or GPVI collagen receptors during platelet interactions [112–114]. Platelet dense granule membranes also contain lysosomal associated membrane proteins (LAMPs), which aid in the breakdown cellular debris [115,116]. The release of neurotransmitters serotonin (5-hydroxytryptamine; 5-HT), epinephrine, and histamine can potentiate ADP-induced platelet activation and aggregation [109,110,117].

Threat Response and Damage Control

Also as part of their first responder characteristics, platelets actively transmigrate across any leaky or inflamed vessel wall in response to a variety of stimuli to aid in wound sterilization and tissue regeneration [118–124]. Stromal cell-derived factor-1 (SDF1 or C-X-C chemokine ligand 12: CXCL12) acts as a very potent stimulus that triggers platelet migration into extravascular spaces [125–130]. In addition to CXCL12, platelets release many transmigration stimulating chemokines and cytokines, CXCL1 (GRO-α), CXCL4 (Platelet Factor 4, PF4), CXCL5 (epithelial-derived neutrophil-activating peptide-78; ENA-78), CXCL7 (Pro-Platelet basic protein, PPBP; β-Thromboglobulin, βTG), and CXCL8

(interleukin-8; IL8) among numerous others from storage granules. Once released from platelets these factors can initiate the migration and invasion of additional platelets, immune cells (neutrophils macrophages and leukocytes), as well as bone marrow progenitor and endothelial progenitor cells or tumor cells [131–134]. The notion of “first responders” is further strengthened by the discovery of C-X-C chemokine receptor 4 & 7 (CXCR-4, CXCR7) the cognate receptors for SDF1: CXCL12 on platelets. As part of their immune surveillance properties, platelets can recognize foreign bodies or invading pathogens [1,135–137]. Additional inflammation and pathogen defense mediating receptors on platelets and pathogen signals, include; toll-like receptors (TLRs), sialic acid-binding immunoglobulin-type lectins (Siglecs), damage associated molecular patterns (DAMPs, e.g. alarmins), infectious pathogens harboring pathogen associated molecular patterns (PAMPs), platelet C-type lectin-like type II transmembrane receptor (CLEC-2), complement receptor type 2 (CR-2), C–C chemokine receptors (CCR 1,3 and 4), dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and coxsackie adenovirus receptor (CAR) [138–141,121,142–149]. Self-associated molecular patterns SAMPs that can be mimicked by pathogens have also been proposed but their disposition and influence on platelets remains to be fully determined [150]. Utilizing these immediate-threat sensing receptors to rapidly initiate migration during potential first responses, platelets are ideally suited for movement because of the highly active cytoskeletal responses linked to activation, adhesion and aggregation [18,151,152,1,153,36]. Platelets are more streamlined and suited for vascular transmigration, not only because they are small in size and minimal displacement volume coupled with their highly active cytoskeleton [154–156]. An even greater vascular transmigration advantage may arise from being unencumbered by the presence of nuclei, which limits the migration of other immune cells [154–157,127]. The absence of nuclei may also limit the distance that platelets can move into tissue. Due to limited protein synthesis capabilities, they cannot indefinitely maintain the replacement of proteins [158,159]. All of these immune surveillance and rapid response properties facilitate speedy sterilization and quickly initiate the repair process during the wound response.

Platelet Mediated Thrombogenesis, Inflammatory, and Resolution Responses

Platelets release membrane fragments with bioactive molecules in the form of platelet microparticles (PMPs) on activation, permitting distant effects [160–164]. Platelet cytoskeletal rearrangement results in budding of PMPs, which exposes phosphatidyl serine (PS), membrane antigens (Ag), and cytoplasm components. The exposure PS-Ag-Cyto complexes on the outer leaflet of PMP creates surface for assembly of a Factor V and Factor Xa catalytic complexes that generate thrombin. Thrombin-mediated cleavage of fibrinogen leads to fibrin clot formation and entrapment of additional platelets at wound sites [165–168]. Fibrinolysis then ensues to control clot growth [165,166]. PMPs also interact with immune cells via adhesion molecules such as selectins that selectively bind carbohydrate molecules associated with immune function [121,169,142,144]. Aggregates can have additional immune functions such as neutrophil ensnared traps (NETs), which are collections of DNA and anti-microbial biomolecules [145,170].

Platelets help initiate or coordinate the immune responses as key subcomponents of the system [121,169,144–147]. They initiate inflammation by releasing a heterogeneous mix of protein molecules that include, transforming growth factor beta (TGF- β), P-selectin, CD40L and RANTES[171–173,121]. These molecules are an assortment of cytokines and adhesion molecules that directly bind or activate or elicit homing responses for monocytes, neutrophils and even T-lymphocytes as chemoattractants to the endothelium, inhibit apoptotic signals and promotes extravasation into affected sites [169,121,142,144]. Platelets can also activate the complement system of which, C3a and C5a are potent anaphylatoxins that amplify inflammatory responses.

The first responder role to threats is thought to be the reason why platelets evolved to have both haemostatic and immune properties [174,2,175,176,163]. This is best highlighted in the wound response model whereby platelets have a unique role in recognizing tissue damage and stimulating more specialized immune cells to infiltrate and initiate the sterilization of the area, particularly where a pathogen may have been introduced past physical barriers. In studies of skin injury, these phases have been described crudely into haemostasis, inflammation, proliferation and resolution. Platelets with a primary role in haemostasis are uniquely poised to initiate inflammation synergistically with resident cells within damaged tissues such as macrophages. Other non-immune resident cells that platelets stimulate include fibroblasts. These evolve into myofibroblasts as they enter the granulomatous tissue that leads to resolution and retraction.[177–179]. Platelet release of TGF- β and extracellular matrix (ECM) tension, help drive fibroblasts to transition into a myofibroblast phenotype that help with repair [180,181]. It also enhances mesenchymal stem cells (MSCs) differentiation and functions as a mechano-stimulatory factor to improve wound closure [182]. Platelet TGF- β also helps neutrophils infiltrate into wounds that are replaced by macrophages. These immune cells initially to acquire a pro-inflammatory phenotype during wound inflammation and proliferation phases and then facilitates myeloid polarization of macrophages and neutrophils towards immunosuppressive phenotypes during tissue repair and resolution phases [183–186]. Platelets are thereby intrinsically linked to the immune and wound repair system.

Platelet “First Response” Facilitated Cancer Progression

Cancer is generally considered as a chronic or non-healing wound [187–189] that can continuously engage platelets any time exposure to tumor components occurs. As a part of the metastatic process, platelet receptors recognize complexes of tumor cell receptors surface bound matrix proteins or cellular products as they invade blood vessels due to platelet-tumor cell first response interactions [130,2,190]. Extensive membrane changes occur at bilayer interfaces between platelets and tumor cells [2,1,191,192]. Tumor cells form extensive membrane/cytoskeletal processes that heavily interdigitate with a central platelet aggregate and involves the uptake of platelet fragments and mitochondria [2,1,191,192]. These interactions are thought to result in the suppression of immune recognition/cytotoxicity or the promotion of cell arrest at the endothelium, or entrapment in the microvasculature. These responses all support survival and spread of cancer cells and the establishment of secondary lesions. Additional mechanisms of the platelet-metastasis relationship may include the production of platelet exosomes or extravascular migratory

behavior of platelets helping to drive cancer progression or preconditioning of secondary metastatic sites [2,1,191,192]. In contrast to the many mechanisms involved in platelet-metastasis relationships, little is known about the role of platelets in precancerous lesion development. This paucity of knowledge exists despite numerous large randomized clinical trials illustrating the cancer preventive effects of non-steroidal anti-inflammatory drugs (NSAIDs), particularly aspirin in reducing the cancer incidence, mortality and metastasis [193–195]. Additional aspirin studies also reduced cancer incidence and all-cause mortality [196–199]. In the case of prior colorectal cancer [200] or colorectal adenomas, [201] those taking aspirin showed fewer new adenomas compared to controls. In The Colorectal Adenoma/Carcinoma Prevention Programme (CAPP) trial aspirin reduced adenomas in Lynch syndrome patients [202]. In the ASPIRin Intervention for the REDuction of colorectal cancer risk (ASPIRED) trial, the effects of aspirin will also be examined using various biomarker endpoints [203]. The ASPIRED study will determine how aspirin influences adenoma biology.

Aspirin covalently acetylates and inactivates platelet cyclooxygenase 1 and thereby eliminates all downstream prostaglandin production from arachidonic acid (AA) by platelets [193]. This includes the key bioactive lipid involved in platelet activation, TxA_2 , which can be counterbalanced by PGI_2 and its analogs that inhibit platelet activation [204,192,205]. Metabolically, the genesis of TxA_2 and other bioactive lipids are also impacted by ω -3 polyunsaturated fatty acid substrate substitution for AA [193]. Although not well studied, this places platelets not only at the center of the metastasis discussion but also the progression of pre-malignancies. Since neoangiogenesis produces leaky blood vessels during early cancer progression, it stands to reason that platelets are the “First Responders” to extravasate, activate and release their stroma stimulating, proangiogenic, chemoattractive, and immunomodulatory contents [2,1]. These normal platelet functions and products undoubtedly promote precancerous lesion progression as a series of cyclic amplification events. Platelets are suspected to have a key role within the full spectrum of the cancer progression continuum, which makes limiting their first response an important target for both prevention and therapy.

Platelets as “First Responders” in Cancer Metastasis

“First Responders” describes platelets as active participants in metastatic processes [1]. Platelets are thought to facilitate cancer and metastasis by various mechanisms [1,192,206,207]. Due to these combined properties, during metastasis circulating platelets can also elicit a first response to the exposure, sloughing or active invasion of tumor cells into the blood stream at primary tumor sites. Obstruction of blood flow and angiogenesis associated with primary tumor growth is likely to further enhance the probability of platelet/tumor cell encounters through membrane interactions [208–210]. The net result is likely to be platelet activation either to subdue cells at the primary site or generate tumor cell platelet emboli in circulation [191,19,1]. Based on such significant numbers in circulation, small size, biophysical shear properties, adhesion, aggregation, and streamline migration properties, platelets are well suited to serve as “First Responders” to a variety of pathologic stimuli, including metastasis.

Tumor cell migration, invasion and intravasation

The proliferation and migration of cancer cells within primary tumors drives a number of events that can impact metastasis [211–215]. Direct impact can occur by shedding, sloughing or active entry of tumor cells into the blood vessels. Based on single cell profiling of circulating tumor cells (CTCs) there is a large diversity of cells found in the circulation that reflect tumor heterogeneity [216,217]. Within the diversity spectrum, CTCs also frequently exhibit stem cell properties [218]. A variety of triggers can initiate entry of CTCs into the circulation. For example, decreased availability of blood vessels can increase the induction of hypoxia as tumors out grow their blood supply and release of angiogenesis or wounding related factors [219–221]. These factors stimulate the formation of new blood vessels that are typically abnormal and leaky, enabling entry of tumor cells into the blood stream [222–224]. Although not extensively studied, there is also potential for leakage or migration of platelets into the tumor that may further enhance the angiogenesis/leaky blood vessel genesis cycle [225,125,226,227]. More aggressive tumor cells that enter the circulation often undergo epithelial-mesenchymal transition EMT [228]. In fact, direct signaling between platelets and cancer cells induces an EMT and promotes metastasis *in vitro* and *in vivo* [229–231]. Cells with EMT characteristics are more fibroblastic in morphology and are typically much more motile and invasive as a result [230,229]. These EMT cells are prone to actively invade blood vessels by using matrix metalloproteinase (MMP) to digest the extracellular matrix and basement membrane of blood vessels [232,233]. As a part of the invasion process interactions between platelets and tumor cells increase the production of MMP-9 [230]. This tumor cell invasive process is termed intravasation and is considered an early dissemination step of the hematogenous metastatic cascade [234].

Hematogenous Spread, Extravasation and Secondary Site Metastasis

Billroth in 1878 was the first to identify cancer cell-containing thrombi with the spread of tumors [235]. Wood first observed real-time arrest and formation of platelet thrombi along with tumor cell migration into the perivascular spaces [236,207]. Baserga and Safi-Otti observed the intravascular arrest and proliferation of anaplastic carcinoma (T1SO) cells prior to extravasation. Both studies identified thrombus formation and tumor cell arrest in small arterioles [237,236,207]. When tumor growth occurred intravascularly, it resulted in the destruction of the vessel then tumor cell extravasation. Jones *et al.* observed the formation of tumor cell-platelet emboli and fibrin using electron microscopy and immunofluorescence after tail vein injection in rats [238]. Early stage emboli formation revealed neutrophils and lymphocytes followed by fibrin formation even after the disappearance of platelets [239] confirmed by others [240]. The release of platelet vesicles and adhesion to vessel walls was observed *in vitro* [241] along with tumor cell migration through the endothelial layer from the adherent embolus [242]. Rat AH-130 ascites hepatoma cells also revealed tumor cell-platelet emboli in microvessels of the lung [243]. Gastpar also performed intravital capillary microscopy in the mesentery of rats to test sulfinpyrazone inhibition of lethal pulmonary tumor cell emboli [244].

Advancements in time-lapse, deep-tissue imaging using intravital microscopy have demonstrated the importance of tumor cell migration *in vivo* [245]. Invasion through the genesis of invadopodia illustrate a dependence on prostaglandin signaling [246]. Intravital fluorescence microscopy has also revealed dynamic platelet-melanoma cell interactions in mice [247]. Platelet depletion significantly reduced melanoma cell adhesion to the injured vascular wall *in vivo* [247]. Platelet interactions and metastasis of B16 melanoma cells to the lungs were decreased after treatment with mAb blocking the $\alpha_{IIb}\beta_3$ or $\alpha_v\beta_3$ integrin [247]. Platelets from the perivascular space can also migrate into extravascular tissues in support of tumor cell invasion and formation of metastases [125–129,1,230]. However, the lack of nuclei and protein synthesis may limit the distance that platelets migrate because they cannot indefinitely sustain the replacement of proteins [158,159]. Thus platelets may potentially prepare or enable extravasation at secondary metastatic sites [67,248–250,2,130,251]. The use of intravital microscopy coupled with fluorescent platelets is expected to reveal even more details of this rapidly occurring process.

Enzymatic digestion of minced tumor fragments using collagenase, and trypsin inhibitors followed by counterflow centrifugal retained the representative receptor expression profile and other intrinsic properties that are closer to the native tumor state. Tail vein injections of these pure tumor cell preparations into syngeneic mice enabled accurate characterization of the resulting intravascular biology *in vivo* [252,191]. In these experiments, platelet-aggregating activities of Lewis lung carcinoma, B16 amelanotic melanoma and 16C mammary adenocarcinoma resulted in tumor cell-platelet emboli formation in the lungs [191]. Platelets aggregated with tumor cells as early as 2 min followed by biphasic association with arrested tumor cells that peaked at 10–30 min and 4–24 h [191]. Ultrastructurally, tumor cells formed processes that extended into the platelet aggregate. At early time intervals (2–10 min), intravascular platelet degranulation in association with tumor cell processes. Tumor cells also engulfed platelet fragments *in vivo* [191]. Follow-up studies using the same models focused on tumor cell interactions with endothelial cells and the subendothelial matrix [19]. Mitoses were observed after 24 h with cell division and the development of intravascular tumor nodules. The final step in the extravasation sequence was dissolution of the basement membrane by the attached tumor cells [19]. In other mouse studies, platelet adhesive glycoprotein receptors and their counterparts expressed by tumor cells participated in tumor cell induced platelet aggregation (TCIPA) as an early step in the development of metastatic lesions [253].

Thrombocytosis

Cancer induces thrombocytosis resulting in elevated circulating platelets linked to Trousseau's syndrome [254–256]. A multicenter study of epithelial ovarian cancer revealed mechanistic associations between platelet counts and disease outcome [130]. Thrombocytosis associated with tumor interleukin-6 (IL-6) and liver generated thrombopoietin has been associated with shortened survival in ovarian cancer patients [130]. Orthotopic ovarian mouse models revealed tumor-derived IL-6 stimulated hepatic thrombopoietin synthesis and paraneoplastic induction of thrombocytosis [130]. These studies showed a paracrine link between cancer and thrombocytosis. More CD63-positive platelet microparticles were also found in the circulation of ovarian cancer patients

compared to those with benign tumors [257]. Procoagulant microparticles were found along with venous thromboemboli in cancer patients [258,259]. The impact of IL6 on thrombocytosis has been observed elsewhere and in other cancers [260,261].

Next Response?

This overview illustrates the importance of platelet “First Responder” characteristics to hemostasis wound repair, cancer immune function and cancer biology. Thrombocytosis and thrombogenesis remain key areas of interest for biologic and prognostic characteristics of cancer. The critical nature of platelets to carcinogenesis as well as platelet-tumor cell heterotypic emboli to metastasis will continue to advance. Advancements in intravital microscopy coupled with fluorescent platelets is expected to facilitate elucidation of the rapid process of platelet-tumor cell invasion. The impact of platelets on tumor immunity are exciting new fields of interest with a bright rapidly responding future.

Acknowledgments

Grant and Other Support: Boone Pickens Distinguished Chair for Early Prevention of Cancer, Duncan Family Institute, Colorectal Cancer Moon Shot, 1R01CA187238-01, 5R01CA172670-03 and 1R01CA184843-01A1, CA177909, and the American Cancer Society Research Professor Award.

References

1. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. *Cancer Metastasis Rev.* 2014; 33(1):231–269. [PubMed: 24696047]
2. Menter, D., Davis, J., Tucker, S., Hawk, E., Crissman, J., Sood, A., et al. Platelets “First Responders” in Cancer Progression and Metastasis. In: Gresele, P.Kleiman, N.Lopez, J., Page, C., editors. *Platelets in Thrombotic and Non-Thrombotic Disorders*. Vol. 2. Switzerland: Springer International Publishing; 2017. p. 1111-1132.
3. Leunissen TC, Wisman PP, van Holten TC, de Groot PG, Korporaal SJ, Koekman AC, et al. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays. *Platelets.* 2016;1–9. [PubMed: 26695713]
4. Liu X, Li Y, Zhu H, Zhao Z, Zhou Y, Zaske AM, et al. Use of non-contact hopping probe ion conductance microscopy to investigate dynamic morphology of live platelets. *Platelets.* 2015; 26(5): 480–485. [PubMed: 25101754]
5. Lof A, Muller JP, Benoit M, Brehm MA. Biophysical approaches promote advances in the understanding of von Willebrand factor processing and function. *Adv Biol Regul.* 2017; 63:81–91. [PubMed: 27717713]
6. Heijnen, H., Korporaal, S. Platelet Morphology and Ultrastructure. In: Gresele, P.Kleiman, N.Lopez, J., Page, C., editors. *Platelets in Thrombotic and Non-Thrombotic Disorders*. Vol. 2. Switzerland: Springer International Publishing; 2017. p. 21-37.
7. O’Brien S, Kent NJ, Lucitt M, Ricco AJ, McAtamney C, Kenny D, et al. Effective hydrodynamic shaping of sample streams in a microfluidic parallel-plate flow-assay device: matching whole blood dynamic viscosity. *IEEE Trans Biomed Eng.* 2012; 59(2):374–382. [PubMed: 22020664]
8. Jen CJ, Tai YW. Morphological study of platelet adhesion dynamics under whole blood flow conditions. *Platelets.* 1992; 3(3):145–153. [PubMed: 21043907]
9. Folie BJ, McIntire LV. Mathematical analysis of mural thrombogenesis. Concentration profiles of platelet-activating agents and effects of viscous shear flow. *Biophys J.* 1989; 56(6):1121–1141. [PubMed: 2611327]
10. Fedosov DA, Noguchi H, Gompper G. Multiscale modeling of blood flow: from single cells to blood rheology. *Biomech Model Mechanobiol.* 2014; 13(2):239–258. [PubMed: 23670555]

11. Kumar A, Graham MD. Mechanism of margination in confined flows of blood and other multicomponent suspensions. *Phys Rev Lett*. 2012; 109(10):108102. [PubMed: 23005332]
12. Tokarev AA, Butylin AA, Ataulakhanov FI. Platelet adhesion from shear blood flow is controlled by near-wall rebounding collisions with erythrocytes. *Biophys J*. 2011; 100(4):799–808. [PubMed: 21320422]
13. Tokarev AA, Butylin AA, Ermakova EA, Shnol EE, Panasenkov GP, Ataulakhanov FI. Finite platelet size could be responsible for platelet margination effect. *Biophys J*. 2011; 101(8):1835–1843. [PubMed: 22004736]
14. Lee SY, Ferrari M, Decuzzi P. Design of bio-mimetic particles with enhanced vascular interaction. *J Biomech*. 2009; 42(12):1885–1890. [PubMed: 19523635]
15. Stukelj R, Schara K, Bedina-Zavec A, Sustar V, Pajnic M, Paden L, et al. Effect of shear stress in the flow through the sampling needle on concentration of nanovesicles isolated from blood. *Eur J Pharm Sci*. 2017; 98:17–29. [PubMed: 27737793]
16. De Gruttola S, Boomsma K, Poulikakos D. Computational simulation of a non-newtonian model of the blood separation process. *Artif Organs*. 2005; 29(12):949–959. [PubMed: 16305650]
17. Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. *Nat Med*. 2009; 15(6):665–673. [PubMed: 19465929]
18. Menter DG, Steinert BW, Sloane BF, Gundlach N, O’Gara CY, Marnett LJ, et al. Role of platelet membrane in enhancement of tumor cell adhesion to endothelial cell extracellular matrix. *Cancer Res*. 1987; 47(24 Pt 1):6751–6762. [PubMed: 2824041]
19. Crissman JD, Hatfield JS, Menter DG, Sloane B, Honn KV. Morphological study of the interaction of intravascular tumor cells with endothelial cells and subendothelial matrix. *Cancer Res*. 1988; 48(14):4065–4072. [PubMed: 3383198]
20. Walsh TG, Metharom P, Berndt MC. The functional role of platelets in the regulation of angiogenesis. *Platelets*. 2015; 26(3):199–211. [PubMed: 24832135]
21. Kim KH, Barazia A, Cho J. Real-time imaging of heterotypic platelet-neutrophil interactions on the activated endothelium during vascular inflammation and thrombus formation in live mice. *J Vis Exp*. 2013; (74)
22. Spectre G, Zhu L, Ersoy M, Hjemdahl P, Savion N, Varon D, et al. Platelets selectively enhance lymphocyte adhesion on subendothelial matrix under arterial flow conditions. *Thromb Haemost*. 2012; 108(2):328–337. [PubMed: 22688347]
23. Gardiner, E., Andrews, R. Platelet Adhesion. In: Gresele, P., Kleiman, N., Lopez, J., Page, C., editors. *Platelets in Thrombotic and Non-Thrombotic Disorders*. Vol. 2. Switzerland: Springer International Publishing; 2017. p. 309-319.
24. Pothapragada S, Zhang P, Sheriff J, Livelli M, Slepian MJ, Deng Y, et al. A phenomenological particle-based platelet model for simulating filopodia formation during early activation. *Int J Numer Method Biomed Eng*. 2015; 31(3):e02702. [PubMed: 25532469]
25. Kunert S, Meyer I, Fleischhauer S, Wannack M, Fiedler J, Shivdasani RA, et al. The microtubule modulator RanBP10 plays a critical role in regulation of platelet discoid shape and degranulation. *Blood*. 2009; 114(27):5532–5540. [PubMed: 19801445]
26. Jackson SP, Nesbitt WS, Westein E. Dynamics of platelet thrombus formation. *J Thromb Haemost*. 2009; 7(Suppl 1):17–20. [PubMed: 19630759]
27. Italiano JE Jr, Bergmeier W, Tiwari S, Falet H, Hartwig JH, Hoffmeister KM, et al. Mechanisms and implications of platelet discoid shape. *Blood*. 2003; 101(12):4789–4796. [PubMed: 12586623]
28. Hartwig JH, Barkalow K, Azim A, Italiano J. The elegant platelet: signals controlling actin assembly. *Thromb Haemost*. 1999; 82(2):392–398. [PubMed: 10605729]
29. White JG, Rao GH. Microtubule coils versus the surface membrane cytoskeleton in maintenance and restoration of platelet discoid shape. *Am J Pathol*. 1998; 152(2):597–609. [PubMed: 9466587]
30. Polanowska-Grabowska R, Geanacopoulos M, Gear AR. Platelet adhesion to collagen via the alpha 2 beta 1 integrin under arterial flow conditions causes rapid tyrosine phosphorylation of pp125FAK. *Biochem J*. 1993; 296(Pt 3):543–547. [PubMed: 8280049]

31. Falet, H. Anatomy of the Platelet Cytoskeleton. In: Gresele, P. Kleiman, N. Lopez, J., Page, C., editors. *Platelets in Thrombotic and Non-Thrombotic Disorders*. Vol. 2. Switzerland: Springer International Publishing; 2017. p. 139-156.
32. Nurden AT, Nurden P. Congenital platelet disorders and understanding of platelet function. *Br J Haematol*. 2014; 165(2):165–178. [PubMed: 24286193]
33. Coburn LA, Damaraju VS, Dozic S, Eskin SG, Cruz MA, McIntire LV. GPIIb/IIIa-vWF rolling under shear stress shows differences between type 2B and 2M von Willebrand disease. *Biophys J*. 2011; 100(2):304–312. [PubMed: 21244826]
34. Colace TV, Diamond SL. Direct observation of von Willebrand factor elongation and fiber formation on collagen during acute whole blood exposure to pathological flow. *Arterioscler Thromb Vasc Biol*. 2013; 33(1):105–113. [PubMed: 23104847]
35. Fredrickson BJ, Dong JF, McIntire LV, Lopez JA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. *Blood*. 1998; 92(10):3684–3693. [PubMed: 9808562]
36. Jackson SP, Mistry N, Yuan Y. Platelets and the injured vessel wall-- “rolling into action”: focus on glycoprotein Ib/V/IX and the platelet cytoskeleton. *Trends Cardiovasc Med*. 2000; 10(5):192–197. [PubMed: 11282294]
37. Yago T, Lou J, Wu T, Yang J, Miner JJ, Coburn L, et al. Platelet glycoprotein Ib/IIIa forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. *J Clin Invest*. 2008; 118(9):3195–3207. [PubMed: 18725999]
38. Clemetson KJ. A short history of platelet glycoprotein Ib complex. *Thromb Haemost*. 2007; 98(1):63–68. [PubMed: 17597992]
39. Li R, Emsley J. The organizing principle of the platelet glycoprotein Ib-IX-V complex. *J Thromb Haemost*. 2013; 11(4):605–614. [PubMed: 23336709]
40. Bernard J, Soulier J. Sur une nouvelle variété de dystrophie thrombocytaire-hémorragique congénitale. *Semin Hôp Paris*. 1948; 24:3217–3223.
41. Ozaki Y, Suzuki-Inoue K, Inoue O. Platelet receptors activated via multimerization: glycoprotein VI, GPIb-IX-V, and CLEC-2. *J Thromb Haemost*. 2013; 11(Suppl 1):330–339. [PubMed: 23809136]
42. Bernardo A, Ball C, Nolasco L, Choi H, Moake JL, Dong JF. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. *J Thromb Haemost*. 2005; 3(3):562–570. [PubMed: 15748247]
43. De Ceunynck K, De Meyer SF, Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. *Blood*. 2013; 121(2):270–277. [PubMed: 23093621]
44. Desch A, Strozyk EA, Bauer AT, Huck V, Niemeyer V, Wieland T, et al. Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin α v β 5-induced secretion of VEGF-A. *Am J Pathol*. 2012; 181(2):693–705. [PubMed: 22659470]
45. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin α IIb β 3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. *Blood*. 2008; 112(8):3011–3025. [PubMed: 18840725]
46. Kim C, Kim MC. Differences in alpha-beta transmembrane domain interactions among integrins enable diverging integrin signaling. *Biochem Biophys Res Commun*. 2013; 436(3):406–412. [PubMed: 23747731]
47. Kim C, Lau TL, Ulmer TS, Ginsberg MH. Interactions of platelet integrin α IIb β 3 transmembrane domains in mammalian cell membranes and their role in integrin activation. *Blood*. 2009; 113(19):4747–4753. [PubMed: 19218549]
48. Shattil SJ. The β 3 integrin cytoplasmic tail: protein scaffold and control freak. *J Thromb Haemost*. 2009; 7(Suppl 1):210–213. [PubMed: 19630802]
49. Nurden AT, Caen JP. An abnormal platelet glycoprotein pattern in three cases of Glanzmann’s thrombasthenia. *Br J Haematol*. 1974; 28(2):253–260. [PubMed: 4473996]
50. Phillips DR, Jenkins CS, Luscher EF, Larrieu M. Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. *Nature*. 1975; 257(5527):599–600. [PubMed: 1172605]

51. Glanzmann E. Hereditäre hamorrhagische thrombasthenie. Beitr Pathologie Blutplättchen J Kinderkt. 1918; 88:113–141.
52. Zhang C, Zhang L, Zhang Y, Sun N, Jiang S, Fujihara TJ, et al. Development of antithrombotic nanoconjugate blocking integrin $\alpha 2 \beta 1$ -collagen interactions. Sci Rep. 2016; 6:26292. [PubMed: 27195826]
53. Szanto T, Joutsu-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. Semin Thromb Hemost. 2012; 38(1):55–63. [PubMed: 22314604]
54. Maurer E, Schaff M, Receveur N, Bourdon C, Mercier L, Nieswandt B, et al. Fibrillar cellular fibronectin supports efficient platelet aggregation and procoagulant activity. Thromb Haemost. 2015; 114(6):1175–1188. [PubMed: 26245230]
55. McCarty OJ, Zhao Y, Andrew N, Machesky LM, Staunton D, Frampton J, et al. Evaluation of the role of platelet integrins in fibronectin-dependent spreading and adhesion. J Thromb Haemost. 2004; 2(10):1823–1833. [PubMed: 15456495]
56. Schaff M, Tang C, Maurer E, Bourdon C, Receveur N, Eckly A, et al. Integrin $\alpha 6 \beta 1$ is the main receptor for vascular laminins and plays a role in platelet adhesion, activation, and arterial thrombosis. Circulation. 2013; 128(5):541–552. [PubMed: 23797810]
57. Inoue O, Suzuki-Inoue K, McCarty OJ, Moroi M, Ruggeri ZM, Kunicki TJ, et al. Laminin stimulates spreading of platelets through integrin $\alpha 6 \beta 1$ -dependent activation of GPVI. Blood. 2006; 107(4):1405–1412. [PubMed: 16219796]
58. Clemetson KJ. Platelet activation: signal transduction via membrane receptors. Thromb Haemost. 1995; 74(1):111–116. [PubMed: 8578442]
59. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest. 1989; 84(5):1440–1445. [PubMed: 2808700]
60. Asselin J, Knight CG, Farndale RW, Barnes MJ, Watson SP. Monomeric (glycine-proline-hydroxyproline)₁₀ repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI. Biochem J. 1999; 339(Pt 2):413–418. [PubMed: 10191274]
61. Kehrel B, Wierwille S, Clemetson KJ, Anders O, Steiner M, Knight CG, et al. Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood. 1998; 91(2):491–499. [PubMed: 9427702]
62. Zahid M, Mangin P, Loyau S, Hechler B, Billiald P, Gachet C, et al. The future of glycoprotein VI as an antithrombotic target. J Thromb Haemost. 2012; 10(12):2418–2427. [PubMed: 23020554]
63. Li P, Qiao JL, Xu KL. Advances of Studies on Platelet GPVI as Antithrombotic Target -Review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017; 25(1):264–269. [PubMed: 28245414]
64. Poulter NS, Pollitt AY, Owen DM, Gardiner EE, Andrews RK, Shimizu H, et al. Clustering of glycoprotein VI (GPVI) dimers upon adhesion to collagen as a mechanism to regulate GPVI signaling in platelets. J Thromb Haemost. 2017; 15(3):549–564. [PubMed: 28058806]
65. Pierre S, Linke B, Suo J, Tarighi N, Del Turco D, Thomas D, et al. GPVI and Thromboxane Receptor on Platelets Promote Proinflammatory Macrophage Phenotypes during Cutaneous Inflammation. J Invest Dermatol. 2017; 137(3):686–695. [PubMed: 27818280]
66. Bergmeier W, Stefanini L. Platelet ITAM signaling. Curr Opin Hematol. 2013; 20(5):445–450. [PubMed: 23921514]
67. Takemoto A, Okitaka M, Takagi S, Takami M, Sato S, Nishio M, et al. A critical role of platelet TGF- β release in podoplanin-mediated tumour invasion and metastasis. Sci Rep. 2017; 7:42186. [PubMed: 28176852]
68. Nakazawa Y, Sato S, Naito M, Kato Y, Mishima K, Arai H, et al. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood. 2008; 112(5):1730–1739. [PubMed: 18541721]
69. Navarro-Nunez L, Langan SA, Nash GB, Watson SP. The physiological and pathophysiological roles of platelet CLEC-2. Thromb Haemost. 2013; 109(6):991–998. [PubMed: 23572154]
70. Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue O, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006; 107(2):542–549. [PubMed: 16174766]

71. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. *J Biol Chem.* 2007; 282(36):25993–26001. [PubMed: 17616532]
72. Pula B, Witkiewicz W, Dziegiel P, Podhorska-Okolow M. Significance of podoplanin expression in cancer-associated fibroblasts: a comprehensive review. *Int J Oncol.* 2013; 42(6):1849–1857. [PubMed: 23588876]
73. Watson AA, Brown J, Harlos K, Eble JA, Walter TS, O'Callaghan CA. The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2. *J Biol Chem.* 2007; 282(5):3165–3172. [PubMed: 17132623]
74. Watson AA, O'Callaghan CA. Crystallization and X-ray diffraction analysis of human CLEC-2. *Acta Crystallogr Sect F Struct Biol Cryst Commun.* 2005; 61(Pt 12):1094–1096.
75. Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor CLEC-2: from discovery to prospects. *J Thromb Haemost.* 2011; 9(Suppl 1):44–55. [PubMed: 21781241]
76. Johnston GI, Cook RG, McEver RP. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. *Cell.* 1989; 56(6):1033–1044. [PubMed: 2466574]
77. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. *J Cell Biol.* 1985; 101(3):880–886. [PubMed: 2411738]
78. Zarbock A, Muller H, Kuwano Y, Ley K. PSGL-1-dependent myeloid leukocyte activation. *J Leukoc Biol.* 2009; 86(5):1119–1124. [PubMed: 19703898]
79. Picker LJ, Warnock RA, Burns AR, Doerschuk CM, Berg EL, Butcher EC. The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. *Cell.* 1991; 66(5):921–933. [PubMed: 1716182]
80. Polley MJ, Phillips ML, Wayner E, Nudelman E, Singhal AK, Hakomori S, et al. CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis x. *Proc Natl Acad Sci U S A.* 1991; 88(14):6224–6228. [PubMed: 1712483]
81. Foxall C, Watson SR, Dowbenko D, Fennie C, Lasky LA, Kiso M, et al. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide. *J Cell Biol.* 1992; 117(4):895–902. [PubMed: 1374413]
82. Habets KL, Huizinga TW, Toes RE. Platelets and autoimmunity. *Eur J Clin Invest.* 2013; 43(7):746–757. [PubMed: 23617819]
83. Kazmi RS, Cooper AJ, Lwaleed BA. Platelet function in pre-eclampsia. *Semin Thromb Hemost.* 2011; 37(2):131–136. [PubMed: 21370213]
84. Nurden AT. Platelets, inflammation and tissue regeneration. *Thromb Haemost.* 2011; 105(Suppl 1):S13–33. [PubMed: 21479340]
85. Borsig L. The role of platelet activation in tumor metastasis. *Expert Rev Anticancer Ther.* 2008; 8(8):1247–1255. [PubMed: 18699763]
86. Dammaco F, Vacca A, Procaccio P, Ria R, Marech I, Racanelli V. Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. *Clin Exp Med.* 2013; 13(2):85–97. [PubMed: 23456539]
87. Erpenbeck L, Schon MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. *Blood.* 2010; 115(17):3427–3436. [PubMed: 20194899]
88. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. *Nat Rev Cancer.* 2011; 11(2):123–134. [PubMed: 21258396]
89. Gay LJ, Felding-Habermann B. Platelets alter tumor cell attributes to propel metastasis: programming in transit. *Cancer Cell.* 2011; 20(5):553–554. [PubMed: 22094248]
90. Kyriazi V, Theodoulou E. Assessing the risk and prognosis of thrombotic complications in cancer patients. *Arch Pathol Lab Med.* 2013; 137(9):1286–1295. [PubMed: 23991742]
91. McEver RP. Selectin-carbohydrate interactions during inflammation and metastasis. *Glycoconj J.* 1997; 14(5):585–591. [PubMed: 9298691]
92. Dangel O, Mergia E, Karlisch K, Groneberg D, Koesling D, Friebe A. Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition. *J Thromb Haemost.* 2010; 8(6):1343–1352. [PubMed: 20149081]

93. Koziak K, Sevigny J, Robson SC, Siegel JB, Kaczmarek E. Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. *Thromb Haemost.* 1999; 82(5):1538–1544. [PubMed: 10595651]
94. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. *Nature.* 1976; 263(5579):663–665. [PubMed: 802670]
95. Sabetkar M, Naseem KM, Tullett JM, Friebe A, Koesling D, Bruckdorfer KR. Synergism between nitric oxide and hydrogen peroxide in the inhibition of platelet function: the roles of soluble guanylyl cyclase and vasodilator-stimulated phosphoprotein. *Nitric Oxide.* 2001; 5(3):233–242. [PubMed: 11384196]
96. Zimmermann H. Nucleotides and cd39: principal modulatory players in hemostasis and thrombosis. *Nat Med.* 1999; 5(9):987–988. [PubMed: 10470068]
97. Aleman MM, Gardiner C, Harrison P, Wolberg AS. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. *J Thromb Haemost.* 2011; 9(11):2251–2261. [PubMed: 21883880]
98. Feng D, Nagy JA, Pyne K, Dvorak HF, Dvorak AM. Platelets exit venules by a transcellular pathway at sites of F-met peptide-induced acute inflammation in guinea pigs. *Int Arch Allergy Immunol.* 1998; 116(3):188–195. [PubMed: 9693266]
99. Gawaz M, Vogel S. Platelets in tissue repair: control of apoptosis and interactions with regenerative cells. *Blood.* 2013; 122(15):2550–2554. [PubMed: 23963043]
100. Lowenhaupt RW, Glueck HI, Miller MA, Kline DL. Factors which influence blood platelet migration. *J Lab Clin Med.* 1977; 90(1):37–45. [PubMed: 17642]
101. Nathan P. The migration of human platelets in vitro. *Thromb Diath Haemorrh.* 1973; 30(1):173–177. [PubMed: 4788745]
102. Schmidt EM, Munzer P, Borst O, Kraemer BF, Schmid E, Urban B, et al. Ion channels in the regulation of platelet migration. *Biochem Biophys Res Commun.* 2011; 415(1):54–60. [PubMed: 22005466]
103. Banerjee D, Mazumder S, Kumar Sinha A. Involvement of Nitric Oxide on Calcium Mobilization and Arachidonic Acid Pathway Activation during Platelet Aggregation with different aggregating agonists. *Int J Biomed Sci.* 2016; 12(1):25–35. [PubMed: 27127451]
104. Philipose S, Konya V, Lazarevic M, Pasterk LM, Marsche G, Frank S, et al. Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. *PLoS One.* 2012; 7(8):e40222. [PubMed: 22870195]
105. Feletou M, Huang Y, Vanhoutte PM. Vasoconstrictor prostanoids. *Pflugers Arch.* 2010; 459(6):941–950. [PubMed: 20333529]
106. Kandhi S, Zhang B, Froogh G, Qin J, Alruwali N, Le Y, et al. EETs promote hypoxic pulmonary vasoconstriction via constrictor prostanoids. *Am J Physiol Lung Cell Mol Physiol.* 2017 ajplung 00038 02017.
107. Bhagwat SS, Hamann PR, Still WC, Bunting S, Fitzpatrick FA. Synthesis and structure of the platelet aggregation factor thromboxane A₂. *Nature.* 1985; 315(6019):511–513. [PubMed: 4000279]
108. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. *Proc Natl Acad Sci U S A.* 1975; 72(8):2994–2998. [PubMed: 1059088]
109. Fukami MH, Salganicoff L. Human platelet storage organelles. A review. *Thromb Haemost.* 1977; 38(4):963–970. [PubMed: 579698]
110. Koseoglu S, Flaumenhaft R. Advances in platelet granule biology. *Curr Opin Hematol.* 2013; 20(5):464–471. [PubMed: 23839294]
111. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, et al. ADP receptor P2Y₁₂ is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. *Arterioscler Thromb Vasc Biol.* 2004; 24(10):1810–1815. [PubMed: 15308557]
112. Goschnick MW, Jackson DE. Tetraspanins-structural and signalling scaffolds that regulate platelet function. *Mini Rev Med Chem.* 2007; 7(12):1248–1254. [PubMed: 18220977]

113. Haining EJ, Yang J, Tomlinson MG. Tetraspanin microdomains: fine-tuning platelet function. *Biochem Soc Trans.* 2011; 39(2):518–523. [PubMed: 21428931]
114. Protty MB, Watkins NA, Colombo D, Thomas SG, Heath VL, Herbert JM, et al. Identification of Tspan9 as a novel platelet tetraspanin and the collagen receptor GPVI as a component of tetraspanin microdomains. *Biochem J.* 2009; 417(1):391–400. [PubMed: 18795891]
115. Israels SJ, McMillan EM, Robertson C, Singhory S, McNicol A. The lysosomal granule membrane protein, LAMP-2, is also present in platelet dense granule membranes. *Thromb Haemost.* 1996; 75(4):623–629. [PubMed: 8743190]
116. Xu L, Harada H, Taniguchi A. The effects of LAMP1 and LAMP3 on M180 amelogenin uptake, localization and amelogenin mRNA induction by amelogenin protein. *J Biochem.* 2008; 144(4): 531–537. [PubMed: 18676354]
117. Vanags DM, Rodgers SE, Duncan EM, Lloyd JV, Bochner F. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline. *Br J Pharmacol.* 1992; 106(4):917–923. [PubMed: 1393289]
118. Petito, E., Momi, S., Gresele, P. The Migration of Platelets and their Interaction with Other Migrating Cells. In: Gresele, P., Kleiman, N., Lopez, J., Page, C., editors. *Platelets in Thrombotic and Non-Thrombotic Disorders*. Vol. 2. Switzerland: Springer International Publishing; 2017. p. 337–351.
119. Sandri G, Bonferoni MC, Rossi S, Ferrari F, Mori M, Cervio M, et al. Platelet lysate embedded scaffolds for skin regeneration. *Expert Opin Drug Deliv.* 2015; 12(4):525–545. [PubMed: 25297510]
120. Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration. *World J Gastroenterol.* 2017; 23(18):3228–3239. [PubMed: 28566882]
121. Mancuso ME, Santagostino E. Platelets: much more than bricks in a breached wall. *Br J Haematol.* 2017
122. Anitua E, Troya M, Zalduendo M, Orive G. Personalized plasma-based medicine to treat age-related diseases. *Mater Sci Eng C Mater Biol Appl.* 2017; 74:459–464. [PubMed: 28254317]
123. Meschi N, Castro AB, Vandamme K, Quirynen M, Lambrechts P. The impact of autologous platelet concentrates on endodontic healing: a systematic review. *Platelets.* 2016; 27(7):613–633. [PubMed: 27658056]
124. Mlynarek RA, Kuhn AW, Bedi A. Platelet-Rich Plasma (PRP) in Orthopedic Sports Medicine. *Am J Orthop (Belle Mead NJ).* 2016; 45(5):290–326. [PubMed: 27552452]
125. Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelets effects on tumor growth. *Semin Oncol.* 2014; 41(3):359–369. [PubMed: 25023351]
126. Unwith S, Zhao H, Hennes L, Ma D. The potential role of HIF on tumour progression and dissemination. *Int J Cancer.* 2015; 136(11):2491–2503. [PubMed: 24729302]
127. Schmidt EM, Kraemer BF, Borst O, Munzer P, Schonberger T, Schmidt C, et al. SGK1 sensitivity of platelet migration. *Cell Physiol Biochem.* 2012; 30(1):259–268. [PubMed: 22759972]
128. Kraemer BF, Borst O, Gehring EM, Schoenberger T, Urban B, Ninci E, et al. PI3 kinase-dependent stimulation of platelet migration by stromal cell-derived factor 1 (SDF-1). *J Mol Med (Berl).* 2010; 88(12):1277–1288. [PubMed: 20852838]
129. Brandt E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: old players in new games. *Immunol Rev.* 2000; 177:204–216. [PubMed: 11138777]
130. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. *N Engl J Med.* 2012; 366(7):610–618. [PubMed: 22335738]
131. Kraemer BF, Schmidt C, Urban B, Bigalke B, Schwanitz L, Koch M, et al. High shear flow induces migration of adherent human platelets. *Platelets.* 2011; 22(6):415–421. [PubMed: 21413844]
132. Chatterjee M, Huang Z, Zhang W, Jiang L, Hultenby K, Zhu L, et al. Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. *Blood.* 2011; 117(14):3907–3911. [PubMed: 21330475]
133. Shenkman B, Brill A, Brill G, Lider O, Savion N, Varon D. Differential response of platelets to chemokines: RANTES non-competitively inhibits stimulatory effect of SDF-1 alpha. *J Thromb Haemost.* 2004; 2(1):154–160. [PubMed: 14717979]

134. Gleissner CA, von Hundelshausen P, Ley K. Platelet chemokines in vascular disease. *Arterioscler Thromb Vasc Biol.* 2008; 28(11):1920–1927. [PubMed: 18723831]
135. Rossaint J, Zarbock A. Platelets in leucocyte recruitment and function. *Cardiovasc Res.* 2015
136. Garraud O, Berthet J, Hamzeh-Cognasse H, Cognasse F. Pathogen sensing, subsequent signalling, and signalosome in human platelets. *Thromb Res.* 2011; 127(4):283–286. [PubMed: 21071069]
137. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. *Circ Res.* 2007; 100(1):27–40. [PubMed: 17204662]
138. Rath D, Chatterjee M, Borst O, Muller K, Langer H, Mack AF, et al. Platelet surface expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 is associated with clinical outcomes in patients with coronary artery disease. *J Thromb Haemost.* 2015; 13(5):719–728. [PubMed: 25660395]
139. Rafii S, Cao Z, Lis R, Siempos II, Chavez D, Shido K, et al. Platelet-derived SDF-1 primes the pulmonary capillary vascular niche to drive lung alveolar regeneration. *Nat Cell Biol.* 2015; 17(2):123–136. [PubMed: 25621952]
140. Chatterjee M, Seizer P, Borst O, Schonberger T, Mack A, Geisler T, et al. SDF-1alpha induces differential trafficking of CXCR4-CXCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival. *FASEB J.* 2014; 28(7):2864–2878. [PubMed: 24668750]
141. Rath D, Chatterjee M, Borst O, Muller K, Stellos K, Mack AF, et al. Expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary syndrome and association with left ventricular functional recovery. *Eur Heart J.* 2014; 35(6):386–394. [PubMed: 24168792]
142. Iannacone M. Platelet-mediated modulation of adaptive immunity. *Semin Immunol.* 2016; 28(6): 555–560. [PubMed: 27802906]
143. Danese S, Fiocchi C. Endothelial Cell-Immune Cell Interaction in IBD. *Dig Dis.* 2016; 34(1–2): 43–50. [PubMed: 26982700]
144. Chatterjee M, Geisler T. Inflammatory Contribution of Platelets Revisited: New Players in the Arena of Inflammation. *Semin Thromb Hemost.* 2016; 42(3):205–214. [PubMed: 26886394]
145. Carestia A, Kaufman T, Schattner M. Platelets: New Bricks in the Building of Neutrophil Extracellular Traps. *Front Immunol.* 2016; 7:271. [PubMed: 27458459]
146. Lam FW, Vijayan KV, Rumbaut RE. Platelets and Their Interactions with Other Immune Cells. *Compr Physiol.* 2015; 5(3):1265–1280. [PubMed: 26140718]
147. Kapur R, Zufferey A, Boilard E, Semple JW. Nouvelle cuisine: platelets served with inflammation. *J Immunol.* 2015; 194(12):5579–5587. [PubMed: 26048965]
148. Cognasse F, Nguyen KA, Damien P, McNicol A, Pozzetto B, Hamzeh-Cognasse H, et al. The Inflammatory Role of Platelets via Their TLRs and Siglec Receptors. *Front Immunol.* 2015; 6:83. [PubMed: 25784910]
149. Chatterjee M, Rath D, Gawaz M. Role of chemokine receptors CXCR4 and CXCR7 for platelet function. *Biochem Soc Trans.* 2015; 43(4):720–726. [PubMed: 26551719]
150. Varki A. Since there are PAMPs and DAMPs, there must be SAMPs? Glycan “self-associated molecular patterns” dampen innate immunity, but pathogens can mimic them. *Glycobiology.* 2011; 21(9):1121–1124. [PubMed: 21932452]
151. Menter DG, Steinert BW, Sloane BF, Taylor JD, Honn KV. A new in vitro model for investigation of tumor cell-platelet-endothelial cell interactions and concomitant eicosanoid biosynthesis. *Cancer Res.* 1987; 47(9):2425–2432. [PubMed: 3552214]
152. Chopra H, Timar J, Rong X, Grossi IM, Hatfield JS, Fligiel SE, et al. Is there a role for the tumor cell integrin alpha IIb beta 3 and cytoskeleton in tumor cell-platelet interaction? *Clin Exp Metastasis.* 1992; 10(2):125–137. [PubMed: 1371433]
153. Bennett JS, Zigmond S, Vilaire G, Cunningham ME, Bednar B. The platelet cytoskeleton regulates the affinity of the integrin alpha(IIb)beta(3) for fibrinogen. *J Biol Chem.* 1999; 274(36): 25301–25307. [PubMed: 10464255]
154. Breckenridge MT, Egelhoff TT, Baskaran H. A microfluidic imaging chamber for the direct observation of chemotactic transmigration. *Biomed Microdevices.* 2010; 12(3):543–553. [PubMed: 20309736]

155. Ellingsen T, Storgaard M, Moller BK, Buus A, Andersen PL, Obel N, et al. Migration of mononuclear cells in the modified Boyden chamber as evaluated by DNA quantification and flow cytometry. *Scand J Immunol.* 2000; 52(3):257–263. [PubMed: 10972901]
156. Friedl P, Wolf K, Lammerding J. Nuclear mechanics during cell migration. *Curr Opin Cell Biol.* 2011; 23(1):55–64. [PubMed: 21109415]
157. Bdeir K, Gollomp K, Stasiak M, Mei J, Papiewska-Pajak I, Zhao G, et al. Platelet-Specific Chemokines Contribute to the Pathogenesis of Acute Lung Injury. *Am J Respir Cell Mol Biol.* 2017; 56(2):261–270. [PubMed: 27755915]
158. Bruce IJ, Kerry R. The effect of chloramphenicol and cycloheximide on platelet aggregation and protein synthesis. *Biochem Pharmacol.* 1987; 36(11):1769–1773. [PubMed: 3579972]
159. Borisova TA, Markosian RA. Age and biosynthesis and breakdown of thrombocyte proteins. *Biull Eksp Biol Med.* 1977; 83(1):20–21. [PubMed: 856328]
160. Pagel O, Walter E, Jurk K, Zahedi RP. Taking the stock of granule cargo: Platelet releasate proteomics. *Platelets.* 2017; 28(2):119–128. [PubMed: 27928935]
161. Melki I, Tessandier N, Zufferey A, Boilard E. Platelet microvesicles in health and disease. *Platelets.* 2017; 28(3):214–221. [PubMed: 28102737]
162. Wang ZT, Wang Z, Hu YW. Possible roles of platelet-derived microparticles in atherosclerosis. *Atherosclerosis.* 2016; 248:10–16. [PubMed: 26978582]
163. Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. *Blood.* 2015; 126(5):582–588. [PubMed: 26109205]
164. Cointe, S., Lacroix, R., Dignat-George, F. Platelet-Derived Microparticles. In: Gresele, P.Kleiman, N.Lopez, J., Page, C., editors. *Platelets in Thrombotic and Non-Thrombotic Disorders.* Vol. 2. Switzerland: Springer International Publishing; 2017. p. 379-392.
165. Zilberman-Rudenko J, Sylman JL, Lakshmanan HHS, McCarty OJT, Maddala J. Dynamics of blood flow and thrombus formation in a multi-bypass microfluidic ladder network. *Cell Mol Bioeng.* 2017; 10(1):16–29. [PubMed: 28580033]
166. Whyte CS, Mitchell JL, Mutch NJ. Platelet-Mediated Modulation of Fibrinolysis. *Semin Thromb Hemost.* 2017; 43(2):115–128. [PubMed: 28215042]
167. Biolik G, Kokot M, Sznepka M, Swieszek A, Ziaja D, Pawlicki K, et al. Platelet reactivity in thromboelastometry. Revision of the FIBTEM test: a basic study. *Scand J Clin Lab Invest.* 2017; 77(3):216–222. [PubMed: 28276730]
168. Mammadova-Bach E, Ollivier V, Loyau S, Schaff M, Dumont B, Favier R, et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. *Blood.* 2015; 126(5):683–691. [PubMed: 25977585]
169. Kral JB, Schrottmaier WC, Salzmann M, Assinger A. Platelet Interaction with Innate Immune Cells. *Transfus Med Hemother.* 2016; 43(2):78–88. [PubMed: 27226790]
170. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. *Nat Med.* 2007; 13(4):463–469. [PubMed: 17384648]
171. Joshi S, Whiteheart SW. The nuts and bolts of the platelet release reaction. *Platelets.* 2017; 28(2):129–137. [PubMed: 27848265]
172. Suades R, Padro T, Badimon L. The Role of Blood-Borne Microparticles in Inflammation and Hemostasis. *Semin Thromb Hemost.* 2015; 41(6):590–606. [PubMed: 26276937]
173. Gill P, Jindal NL, Jagdis A, Vadas P. Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis. *J Allergy Clin Immunol.* 2015; 135(6):1424–1432. [PubMed: 26051949]
174. Momi, S., Wiwanitkit, V. Phylogeny of Blood Platelets. In: Gresele, P.Kleiman, N.Lopez, J., Page, C., editors. *Platelets in Thrombotic and Non-Thrombotic Disorders.* Vol. 2. Switzerland: Springer International Publishing; 2017. p. 11-19.
175. Roch GJ, Sherwood NM. Glycoprotein hormones and their receptors emerged at the origin of metazoans. *Genome Biol Evol.* 2014; 6(6):1466–1479. [PubMed: 24904013]
176. He W, Tang Y, Qi B, Lu C, Qin C, Wei Y, et al. Phylogenetic analysis and positive-selection site detecting of vascular endothelial growth factor family in vertebrates. *Gene.* 2014; 535(2):345–352. [PubMed: 24200960]

177. Mercer PF, Chambers RC. Coagulation and coagulation signalling in fibrosis. *Biochim Biophys Acta*. 2013; 1832(7):1018–1027. [PubMed: 23298546]
178. Yamaguchi Y, Yoshikawa K. Cutaneous wound healing: an update. *J Dermatol*. 2001; 28(10): 521–534. [PubMed: 11732719]
179. Gerarduzzi C, Di Battista JA. Myofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective. *Inflamm Res*. 2017; 66(6):451–465. [PubMed: 28040859]
180. Greaves NS, Ashcroft KJ, Baguneid M, Bayat A. Current understanding of molecular and cellular mechanisms in fibroplasia and angiogenesis during acute wound healing. *J Dermatol Sci*. 2013; 72(3):206–217. [PubMed: 23958517]
181. Carthy JM. TGFbeta signaling and the control of myofibroblast differentiation: Implications for chronic inflammatory disorders. *J Cell Physiol*. 2017
182. Ghosh D, McGrail DJ, Dawson MR. TGF-beta1 Pretreatment Improves the Function of Mesenchymal Stem Cells in the Wound Bed. *Front Cell Dev Biol*. 2017; 5:28. [PubMed: 28421182]
183. Valcourt U, Carthy J, Okita Y, Alcaraz L, Kato M, Thuault S, et al. Analysis of Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor beta. *Methods Mol Biol*. 2016; 1344:147–181. [PubMed: 26520123]
184. Das UN. Inflammatory bowel disease as a disorder of an imbalance between pro- and anti-inflammatory molecules and deficiency of resolution bioactive lipids. *Lipids Health Dis*. 2016; 15:11. [PubMed: 26762544]
185. Gensel JC, Zhang B. Macrophage activation and its role in repair and pathology after spinal cord injury. *Brain Res*. 2015; 1619:1–11. [PubMed: 25578260]
186. Shinde AV, Frangogiannis NG. Fibroblasts in myocardial infarction: a role in inflammation and repair. *J Mol Cell Cardiol*. 2014; 70:74–82. [PubMed: 24321195]
187. Arwert EN, Hoste E, Watt FM. Epithelial stem cells, wound healing and cancer. *Nat Rev Cancer*. 2012; 12(3):170–180. [PubMed: 22362215]
188. Dovizio M, Sacco A, Patrignani P. Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process. *Vascul Pharmacol*. 2017; 89:1–11. [PubMed: 28089842]
189. Dvorak HF. Tumors: wounds that do not heal-redux. *Cancer Immunol Res*. 2015; 3(1):1–11. [PubMed: 25568067]
190. Lichtenberger L, Fang D, Bick R, Poindexter B, Phan T, Bergeron A, et al. Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1. *Cancer Prevention Res*. 2017; 10:142–152.
191. Menter DG, Hatfield JS, Harkins C, Sloane BF, Taylor JD, Crissman JD, et al. Tumor cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells. *Clin Exp Metastasis*. 1987; 5(1):65–78. [PubMed: 3829498]
192. Menter DG, Harkins C, Onoda J, Riorden W, Sloane BF, Taylor JD, et al. Inhibition of tumor cell induced platelet aggregation by prostacyclin and carbacyclin: an ultrastructural study. *Invasion Metastasis*. 1987; 7(2):109–128. [PubMed: 3294727]
193. Umar A, Steele VE, Menter DG, Hawk ET. Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. *Semin Oncol*. 2016; 43(1):65–77. [PubMed: 26970125]
194. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. *Nat Rev Cancer*. 2016; 16(3):173–186. [PubMed: 26868177]
195. Holmes CE, Jasielec J, Levis JE, Skelly J, Muss HB. Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy. *Clin Transl Sci*. 2013; 6(5):386–390. [PubMed: 24127927]
196. Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. *J Natl Cancer Inst*. 2007; 99(11):881–889. [PubMed: 17551148]
197. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. *Ann Oncol*. 2012; 23(6):1403–1415. [PubMed: 22517822]
198. Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS. Long-term aspirin use and mortality in women. *Arch Intern Med*. 2007; 167(6):562–572. [PubMed: 17389287]

199. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. *Anticancer Res.* 2004; 24(5B):3177–3184. [PubMed: 15510608]
200. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. *N Engl J Med.* 2003; 348(10):883–890. [PubMed: 12621132]
201. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med.* 2003; 348(10):891–899. [PubMed: 12621133]
202. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet.* 2011; 378(9809):2081–2087. [PubMed: 22036019]
203. Drew DA, Chin SM, Gilpin KK, Parziale M, Pond E, Schuck MM, et al. ASPIRin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. *Trials.* 2017; 18(1):50. [PubMed: 28143522]
204. Honn KV, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent. *Science.* 1981; 212(4500):1270–1272. [PubMed: 7015512]
205. Honn KV, Menter D, Cavanaugh PG, Neagos G, Moilanen D, Taylor JD, et al. A review of prostaglandins and the treatment of tumor metastasis. *Acta Clin Belg.* 1983; 38(1):53–67. [PubMed: 6405568]
206. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. *Proc Natl Acad Sci U S A.* 1968; 61(1):46–52. [PubMed: 5246932]
207. Woods JR. Experimental Studies of the Intravascular Dissemination of Ascitic V2 Carcinoma Cells in the Rabbit, with Special Reference to Fibrinogen and Fibrinolytic Agents. *Bull Schweiz Akad Med Wiss.* 1964; 20:92–121. [PubMed: 14145390]
208. Horejsova M, Pavlickova V, Koukolik F, Stritesky J. Morphologic verification of neoplastic portal vein obstruction. *Cas Lek Cesk.* 1995; 134(20):655–657. [PubMed: 7489581]
209. Benazzi C, Al-Dissi A, Chau CH, Figg WD, Sarli G, de Oliveira JT, et al. Angiogenesis in spontaneous tumors and implications for comparative tumor biology. *ScientificWorldJournal.* 2014; 2014:919570. [PubMed: 24563633]
210. Fein MR, Egeblad M. Caught in the act: revealing the metastatic process by live imaging. *Dis Model Mech.* 2013; 6(3):580–593. [PubMed: 23616077]
211. Starke J, Wehrle-Haller B, Friedl P. Plasticity of the actin cytoskeleton in response to extracellular matrix nanostructure and dimensionality. *Biochem Soc Trans.* 2014; 42(5):1356–1366. [PubMed: 25233415]
212. Gritsenko PG, Ilina O, Friedl P. Interstitial guidance of cancer invasion. *J Pathol.* 2012; 226(2):185–199. [PubMed: 22006671]
213. Friedl P, Sahai E, Weiss S, Yamada KM. New dimensions in cell migration. *Nat Rev Mol Cell Biol.* 2012; 13(11):743–747. [PubMed: 23072889]
214. Friedl P, Wolf K, Zegers MM. Rho-directed forces in collective migration. *Nat Cell Biol.* 2014; 16(3):208–210. [PubMed: 24576897]
215. Haeger A, Krause M, Wolf K, Friedl P. Cell jamming: collective invasion of mesenchymal tumor cells imposed by tissue confinement. *Biochim Biophys Acta.* 2014; 1840(8):2386–2395. [PubMed: 24721714]
216. Deng G, Krishnakumar S, Powell AA, Zhang H, Mindrinos MN, Telli ML, et al. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. *BMC Cancer.* 2014; 14:456. [PubMed: 24947048]
217. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. *PLoS One.* 2012; 7(5):e33788. [PubMed: 22586443]
218. Tang J, Gao X, Zhi M, Zhou HM, Zhang M, Chen HW, et al. Plateletcrit: a sensitive biomarker for evaluating disease activity in Crohn's disease with low hs-CRP. *J Dig Dis.* 2015; 16(3):118–124. [PubMed: 25565427]

219. Pasula S, Cai X, Dong Y, Messa M, McManus J, Chang B, et al. Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling. *J Clin Invest*. 2012; 122(12):4424–4438. [PubMed: 23187125]
220. Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. *Recent Results Cancer Res*. 2010; 180:103–114. [PubMed: 20033380]
221. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. *Oncology*. 2005; 69(Suppl 3):4–10. [PubMed: 16301830]
222. Keskin D, Kim J, Cooke VG, Wu CC, Sugimoto H, Gu C, et al. Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. *Cell Rep*. 2015; 10(7):1066–1081. [PubMed: 25704811]
223. Nagy JA, Dvorak AM, Dvorak HF. Vascular hyperpermeability, angiogenesis, and stroma generation. *Cold Spring Harb Perspect Med*. 2012; 2(2):a006544. [PubMed: 22355795]
224. Fukumura D, Jain RK. Imaging angiogenesis and the microenvironment. *APMIS*. 2008; 116(7–8):695–715. [PubMed: 18834413]
225. Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. *Proc Natl Acad Sci U S A*. 2006; 103(4):855–860. [PubMed: 16418262]
226. Schumacher D, Strilic B, Sivaraj KK, Wettschurek N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. *Cancer Cell*. 2013; 24(1):130–137. [PubMed: 23810565]
227. O'Byrne KJ, Steward WP. Tumour angiogenesis: a novel therapeutic target in patients with malignant disease. *Expert Opin Emerg Drugs*. 2001; 6(1):155–174. [PubMed: 15989502]
228. Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, et al. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. *Clin Cancer Res*. 2015; 21(4):899–906. [PubMed: 25516888]
229. Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. *Cancer Discov*. 2012; 2(12):1091–1099. [PubMed: 23166151]
230. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. *Cancer Cell*. 2011; 20(5):576–590. [PubMed: 22094253]
231. van Es N, Sturk A, Middeldorp S, Nieuwland R. Effects of cancer on platelets. *Semin Oncol*. 2014; 41(3):311–318. [PubMed: 25023347]
232. Nistico P, Bissell MJ, Radisky DC. Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. *Cold Spring Harb Perspect Biol*. 2012; 4(2)
233. Gresele P, Falcinelli E, Sebastiano M, Momi S. Matrix Metalloproteinases and Platelet Function. *Prog Mol Biol Transl Sci*. 2017; 147:133–165. [PubMed: 28413027]
234. Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. *Cancer Res*. 1978; 38(9):2651–2660. [PubMed: 354778]
235. Billroth, T. *Lectures on Surgical Pathology and Therapeutics, a Handbook for Students and Practitioners*. Vol. II. London: The New Sydenham Society; 1878.
236. Johnson JH, Woods JR. An in Vitro Study of Fibrinolytic Agents on V2 Carcinoma Cells and Intravascular Thrombi in Rabbits. *Bull Johns Hopkins Hosp*. 1963; 113:335–346. [PubMed: 14089496]
237. Baserga R, Saffiotti U. Experimental studies on histogenesis of blood-borne metastases. *AMA Arch Pathol*. 1955; 59(1):26–34. [PubMed: 13217582]
238. Jones DS, Wallace AC, Fraser EE. Sequence of events in experimental metastases of Walker 256 tumor: light, immunofluorescent, and electron microscopic observations. *J Natl Cancer Inst*. 1971; 46(3):493–504. [PubMed: 4100699]
239. Chew EC, Wallace AC. Demonstration of fibrin in early stages of experimental metastases. *Cancer Res*. 1976; 36(6):1904–1909. [PubMed: 1268844]
240. Warren BA, Vales O. The adhesion of thromboplastic tumour emboli to vessel walls in vivo. *Br J Exp Pathol*. 1972; 53(3):301–313. [PubMed: 5055714]

241. Warren BA, Vales O. The release of vesicles from platelets following adhesion to vessel walls in vitro. *Br J Exp Pathol.* 1972; 53(2):206–215. [PubMed: 4338062]
242. Warren BA. Some aspects of blood borne tumour emboli associated with thrombosis. *Z Krebsforsch Klin Onkol Cancer Res Clin Oncol.* 1976; 87(1):1–15. [PubMed: 136107]
243. Kinjo M. Lodgement and extravasation of tumour cells in blood-borne metastasis: an electron microscope study. *Br J Cancer.* 1978; 38(2):293–301. [PubMed: 698045]
244. Gastpar H. Inhibition of cancer cell stickiness, a model for the testing of in vivo thrombocyte aggregation inhibitors. IV. Effect of sulfinpyrazone. *Fortschr Med.* 1978; 96(36):1823–1827. [PubMed: 700559]
245. Paul CD, Mistriotis P, Konstantopoulos K. Cancer cell motility: lessons from migration in confined spaces. *Nat Rev Cancer.* 2017; 17(2):131–140. [PubMed: 27909339]
246. Tonisen F, Perrin L, Bayarmagnai B, van den Dries K, Cambi A, Gligorijevic B. EP4 receptor promotes invadopodia and invasion in human breast cancer. *Eur J Cell Biol.* 2017; 96(2):218–226. [PubMed: 28094049]
247. Lonsdorf AS, Kramer BF, Fahrleitner M, Schonberger T, Gnerlich S, Ring S, et al. Engagement of alphaIIb beta3 (GPIIb/IIIa) with alphanbeta3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis. *J Biol Chem.* 2012; 287(3):2168–2178. [PubMed: 22102277]
248. Lichtenberger LM, Fang D, Bick RJ, Poindexter BJ, Phan T, Bergeron AL, et al. Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1. *Cancer Prev Res (Phila).* 2017; 10(2):142–152. [PubMed: 27998883]
249. Hu Q, Wang M, Cho MS, Wang C, Nick AM, Thiagarajan P, et al. Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. *BBA Clin.* 2016; 6:76–81. [PubMed: 27453821]
250. Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, et al. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. *J Clin Invest.* 2016; 126(5):1885–1896. [PubMed: 27064283]
251. Qi C, Li B, Guo S, Wei B, Shao C, Li J, et al. P-Selectin-Mediated Adhesion between Platelets and Tumor Cells Promotes Intestinal Tumorigenesis in Apc(Min/+) Mice. *Int J Biol Sci.* 2015; 11(6):679–687. [PubMed: 25999791]
252. Crissman JD, Hatfield J, Schaldenbrand M, Sloane BF, Honn KV. Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study. *Lab Invest.* 1985; 53(4):470–478. [PubMed: 4046557]
253. Oleksowicz L, Mrowiec Z, Schwartz E, Khorshidi M, Dutcher JP, Puszkin E. Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. *Thromb Res.* 1995; 79(3):261–274. [PubMed: 8533122]
254. Bouvenot G, Escande M, Xeridat B, Simonin G, Boucoiran J, Delboy C. Thrombocytosis and cancer. Apropos of a chronological series of 100 patients. *Sem Hop.* 1977; 53(36):1921–1925. [PubMed: 208158]
255. Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? *Cancer Metastasis Rev.* 1992; 11(3–4):325–351. [PubMed: 1423821]
256. Levin J, Conley CL. Thrombocytosis Associated with Malignant Disease. *Arch Intern Med.* 1964; 114:497–500. [PubMed: 14184638]
257. Rank A, Liebhardt S, Zwirner J, Burges A, Nieuwland R, Toth B. Circulating microparticles in patients with benign and malignant ovarian tumors. *Anticancer Res.* 2012; 32(5):2009–2014. [PubMed: 22593480]
258. Nieuwland R, Berckmans RJ, Rottevel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PG, et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. *Circulation.* 1997; 96(10):3534–3541. [PubMed: 9396452]
259. van Doormaal F, Kleinjan A, Berckmans RJ, Mackman N, Manly D, Kamphuisen PW, et al. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. *Thromb Haemost.* 2012; 108(1):160–165. [PubMed: 22535219]

260. Cokic VP, Mitrovic-Ajtic O, Beleslin-Cokic BB, Markovic D, Buac M, Diklic M, et al. Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms. *Mediators Inflamm.* 2015; 2015:453020. [PubMed: 26491227]
261. Matsuo K, Hasegawa K, Yoshino K, Murakami R, Hisamatsu T, Stone RL, et al. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. *Eur J Cancer.* 2015; 51(14):1978–1988. [PubMed: 26238017]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure. Platelet “First Responders” facilitate wound response, threat recognition, immune function, cancer progression and metastasis

Platelets elicit the initial response to any wound or breach in blood vessels. Platelets respond first by adhering to the perivascular extracellular matrix basement membrane and collagen. This causes resting platelets to change shape, aggregate and release both alpha and dense granule components that attract and activate more platelets as well as immune cells. Anucleate platelets are key bone marrow stem cell-megakaryocyte derived subcellular product are attracted to leaky angiogenic vessels and can invade into perivascular spaces. The platelet aggregation process is held in check by prostacyclin (PGI₂). Platelets can also slow in the presence of shear stress of rapidly flowing blood by forming slip-catch bonds with von Willebrand Factor (VWF) that causes rolling behaviour at the endothelial cell surface. A local inflammatory response that follows involves complement (enzymatically processed to C3a and C5a), prostaglandin E₂ (PGE₂), interleukin-6 (IL-6), IL-1alpha (IL1α) and other inflammatory cytokines. Platelets can also interact with ultra large VWF to form tethers. Another first responder behaviour is the recognition of damage by toll-like receptors (TLRs), sialic acid-binding immunoglobulin-type lectins (Siglecs), damage associated molecular patterns (DAMPs), infectious pathogens harboring pathogen associated molecular patterns (PAMPs). Other platelet threat receptors include: C-type lectin-like type II transmembrane receptor (CLEC-2), complement receptor type 2 (CR-2), C–C chemokine receptors (CCR 1,3 and 4), dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and coxsackie adenovirus receptor (CAR) and integrins. Primary tumors secrete IL6, which induces thrombospondin release in the liver and initiates thrombocytosis in the bone marrow. Platelets also induce physical and molecular wounding damage signals. This can lead to further platelet activation and cyclic inflammatory release of tumor and platelet microparticles and exosomes that molecularly and biologically cross-

educate one another along with additional proinflammatory and angiogenic factors. After full intravasation into the blood stream, direct contact with circulating tumor cells (CTCs) initiate tumor cell induced platelet aggregation (TCIPA) that causes further platelet activation and alpha (α) and dense granule release. Alpha granules contain numerous proteins, growth factors such as platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) that stimulate tumor growth and angiogenesis. Dense granule release includes platelet G-protein coupled receptor stimulants such as adenosine diphosphate (ADP) and serotonin (5-HT: 5-hydroxytryptamine). Platelet activation also leads to thromboxane A₂ (TxA₂) synthesis and release. Direct platelet-tumor cell contact glycoproteins such as P-selectin and tissue factor (TF) or via microparticles bearing procoagulants stimulate thrombin production and fibrin clot formation. The heterotypic platelet-tumor cell aggregates help protect them from vascular shear forces and may mask them from other immune cells along with providing a reservoir for growth factors. Following hematogenous spread additional platelets are engaged at secondary sites facilitating and stabilizing the adhesion and arrest of heterotypic emboli prior to extravasation. Released molecules also recruit granulocytes by bone marrow derived cell induction and immune cell differentiation. Transforming growth factor-beta (TGF- β) from platelets and PGE₂ release stimulate marrow derived stem cells (MDSC) and T-cell differentiation or inhibition, which includes: cell cluster of differentiation 8 positive (CD8⁺) cytotoxic T-cells, T-helper1 (T_H1), T-helper17 (T_H17) T-regulatory cells (T_{reg}). Concurrently, bone marrow derived dendritic cells (BMDC) induction can occur in response to cytokines, C-X-C motif chemokine 5 (CXCL-5) and CXCL-7. Secreted TGF- β induces epithelial-mesenchymal-transition (EMT) genes and also facilitates myeloid polarization of macrophages and neutrophils towards immunosuppressive phenotypes. This may occur within the tumor or in the circulation at platelet facilitated arrest sites during the establishment of metastasis. Thus, these platelet-tumor cell microenvironmental niches may direct tumor-associated macrophages (TAMs) toward a protumor (M2) from an antitumor (M1) phenotype. Similarly, tumor-associated neutrophils (TANs) TANs may acquire a protumor phenotype (similar to M2), largely driven by TGF- β to become “N2” neutrophils.